Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: Results from the NATT trial in triple negative or HER2 positive breast cancer

Breast Cancer Research and Treatment

Volumn 142, Issue 3, 2013, Pages 549-558

  Chen, Xiaosong ^a   Ye, Guolin ^b   Zhang, Chenfang ^c   Li, Xinzheng ^d   Chen, Yiding ^e   Xie, Xiaohong ^f   Zheng, Hong ^g   Cao, Yali ^h   Wu, Kejin ^a   Ni, Duo ⁱ   Tang, Jinhai ^j   Wei, Ziguo ^k   Shen, Kunwei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

^c GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^d SHANXI CANCER HOSPITAL   (China)

^e ZHEJIANG UNIVERSITY   (China)

^f Zhejiang Traditional Chinese Medical Hospital   (China)

^g SICHUAN UNIVERSITY   (China)

^h Third Hospital of Nanchang   (China)

ⁱ Xinjiang Uygur Autonomous Region's Hospital   (China)

^j JIANGSU CANCER HOSPITAL   (China)

^k LINYI PEOPLE'S HOSPITAL   (China)

more..

Author keywords

Anthracycline; HER2 positive breast cancer; Neoadjuvant chemotherapy; Pathological complete remission; Prognosis; Triple negative breast cancer

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; RECEPTOR, ERBB-2; TAXOIDS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84890311033     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2761-1     Document Type: Article

References (36)

1. DeSantis C, Siegel R, Bandi P, et al. (2011) Breast cancer statistics. CA Cancer J Clin 61(6):409-418
2. Kaufmann M, von Minckwitz G, Bear HD, et al. (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18:1927-1934
3. Fumagalli D, Bedard PL, Nahleh Z, et al. (2012) A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol 13(6):e240-e248
4. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 7:188-194
5. Rastogi P, Anderson S, Bear HD, et al. (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778-785
6. Berruti A, Generali D, Kaufmann M, et al. (2011) International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr 2011(43):147-151
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432-444
8. Smith IC, Heys SD, Hutcheon AW, et al. (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20(6):1456-1466
9. Mackey JR, Martin M, Pienkowski T, et al. (2013) Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 14(1):72-80
10. Martín M, Seguí MA, Antón A, et al. (2010) Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363(23):2200-2210
11. von Minckwitz G, Kümmel S, Vogel P, et al. (2008) Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 100(8):552-562
12. Aebi S, Davidson T, Gruber G, et al. (2011) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi12-24
13. Dhesy-Thind B, Pritchard KI, Messersmith H, et al. (2008) HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat 109(2):209-229
14. Gennari A, Sormani MP, Pronzato P, et al. (2008) HER-2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100:14-20
15. Slamon D, Eiermann W, Robert N, et al. (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273-1283
16. Jones SE, Savin MA, Holmes FA, et al. (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24(34):5381-5387
17. Chen XS, Nie XQ, Chen CM, et al. (2010) Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Ann Oncol 21(5):961-967
18. Wildiers H, Neven P, Christiaens MR, et al. (2011) Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline- based chemotherapy regimen for patients with locally advanced breast cancer. Ann Oncol 22(3):588-594
19. Burstein HJ, Piccart-Gebhart MJ, Perez EA, et al. (2012) Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol 30(18):2179-2182
20. Perou CM, Sorlie T, Eisen MB, et al. (2000) Molecular portraits of human breast tumours. Nature 406:747-752
21. Goldhirsch A, Wood WC, Coates AS, et al. (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736-1747
22. Rouzier R, Perou CM, Symmans WF, et al. (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678-5685
23. Carey LA, Dees EC, Sawyer L, et al. (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329-2334
24. Singletary SE, Connolly JL (2006) Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 56(1):37-47
25. Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247
26. Gianni L, Eiermann W, Semiglazov V, et al. (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375(9712):377-384
27. Hudis CA, Barlow WE, Costantino JP, et al. (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25(15):2127-2132
28. Huober J, von Minckwitz G, Denkert C, et al. (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124(1):133-140
29. Berry DA (2009) Monitoring accumulating data in a clinical trial. Biometrics 45:1197-1211
30. Khasraw M, Bell R, Dang C (2012) Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast 21(2):142-149
31. Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al. (2010) Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(11):1821-1828
32. Ellis P, Barrett-Lee P, Johnson L, et al. (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 373(9676):1681-1692
33. Burnell MJ, Levine MN, Chapman JA, et al. (2007) A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21). J Clin Oncol 25(suppl 18):550
34. NSABP B-46-I, USOR 07132. http://www.clinicaltrials.gov/ct2/show/ NCT00887536?term=NSABP+TAC+TC&rank=1 Accessed 3 Jan 2013
35. von Minckwitz G, Untch M, Blohmer JU, et al. (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796-1804
36. Gianni L, Dafni U, Gelber RD, et al. (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12(3):236-244